Skip to contentE
Exousia Bio, Inc.
E
LMMYExousia Bio, Inc. Q2 2026 · 10-Q
Revenue$0.00$0.00— vs Q2 2025 Net Income-$19.08K-$19.08KN/M vs Q2 2025 EPS Diluted$0.00$0.00−100.0% vs Q2 2025 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Exousia Bio, Inc. · CIK 1939937 · Engraved from SEC EDGAR
Operating Cash Flowderived$173,126+96.8% ended Nov 30, 2025 · filed Mar 17, 2026 · 107 d after period end